Regression of left ventricular hypertrophy in kidney transplant recipients: The potential role for inhibition of mammalian target of rapamycin

Transplantation Proceedings

Volumn 42, Issue 9 SUPPL., 2010, Pages

  Paoletti, E ^a   Cannella, G ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN INHIBITOR; CYCLOSPORIN A; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDRALAZINE; LISINOPRIL; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; RAPAMYCIN; TACROLIMUS;

ANTIHYPERTENSIVE THERAPY; CLINICAL TRIAL; DRUG MECHANISM; DRUG SUBSTITUTION; GRAFT RECIPIENT; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE FIBROSIS; HEART TRANSPLANTATION; HEART WEIGHT; HUMAN; KIDNEY TRANSPLANTATION; NONHUMAN; PRIORITY JOURNAL; REVIEW;

EID: 78649426029     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2010.07.007     Document Type: Article

References (19)

1. C. Rigatto, R.N. Foley, and G.M. Kent Long-term changes in left ventricular hypertrophy after renal transplantation Transplantation 70 2000 570
2. E. Paoletti, P. Cassottana, and M. Amidone ACE inhibitors and persistent left ventricular hypertrophy after renal transplantation: a randomized clinical trial Am J Kidney Dis 50 2007 133
3. Excerpts from the United States Renal Data System 2009 Annual Data ReportAtlas of Chronic Kidney Disease & End-Stage Renal Disease in the United States Am J Kidney Dis 55 suppl 1 2010 S281
4. C. Rigatto, R.N. Foley, and J. Jeffery Electrocardiographic left ventricular hypertrophy in renal transplant recipients: prognostic value and impact of blood pressure and anemia J Am Soc Nephrol 14 2003 462
5. K.L. Lentine, M.A. Schnitzler, and K.C. Abbott De novo congestive heart failure after kidney transplantation: a common condition with poor prognostic implications Am J Kidney Dis 46 2005 720
6. G.M. London, B. Pannier, and A.P. Guerin Alterations of left ventricular hypertrophy in and survival of patients receiving hemodialysis: follow-up of an interventional study J Am Soc Nephrol 12 2001 2759
7. E. Paoletti, P. Cassottana, and D. Bellino Left ventricular geometry and adverse cardiovascular events in chronic hemodialysis patients on prolonged therapy with ACE inhibitors Am J Kidney Dis 40 2002 728
8. P. Okin, R.B. Devereux, and S. Jern Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events JAMA 292 2004 2396
9. E. Paoletti, M. Gherzi, and M. Amidone Association of arterial hypertension with renal target organ damage in kidney transplant recipients: the predictive role of ambulatory blood pressure monitoring Transplantation 87 2009 1864
10. K. Midtvedt, H. Ihlen, and A. Hartmann Reduction of left ventricular mass by lisinopril and nifedipine in hypertensive renal transplant recipients: a prospective randomized double-blind study Transplantation 72 2001 107
11. D. Hernandez, J. Lacalzada, and E. Salido Regression of left ventricular hypertrophy by lisinopril after renal transplantation: role of ACE gene polymorphism Kidney Int 58 2000 889
12. E. Paoletti, and G. Cannella Reducing the risk of left ventricular hypertrophy in kidney transplant recipients: the potential role of mammalian target of rapamycin Transplant Proc 41 2009 S3
13. T. Shioi, J.R. McMullen, and O. Tarnavski Rapamycin attenuates load-induced cardiac hypertrophy in mice Circulation 107 2003 1664
14. J.R. McMullen, M.C. Sherwood, and O. Tarnavski Inhibition of mTOR signaling with rapamycin regresses established cardiac hypertrophy induced by pressure overload Circulation 109 2004 3050
15. N. Hedhli, M. Pelat, and C. Depre Protein turnover in cardiac cell growth and survival Cardiovasc Res 68 2005 186
16. A.M. Siedlecki, X. Jin, and A.J. Muslin Uremic cardiac hypertrophy is reversed by rapamycin but not by lowering of blood pressure Kidney Int 75 2009 800
17. E. Paoletti, M. Amidone, and P. Cassottana Effect of sirolimus on left ventricular hypertrophy in kidney transplant recipients: a 1-year nonrandomized controlled trial Am J Kidney Dis 52 2008 324
18. E. Raichlin, K. Chandrasekaran, and W.K. Kremers Sirolimus as primary immunosuppressant reduces left ventricular mass and improves diastolic function of the cardiac allograft Transplantation 86 2008 1395
19. S.S. Kushwaha, E. Raichlin, and Y. Sheinin Sirolimus affects cardiomyocytes to reduce left ventricular mass in heart transplant recipients Eur Heart J 29 2008 2742